AUS
NZ
UK
CA
USA
IND
Healthcare
Biotech Sector Activity Across Australian Market
March 18, 2026 12:33 PM AEDT| By SamOrthocell’s nerve repair technology highlights biotechnology innovation within global healthcare, supporting surgical procedures and advancing regenerative medicine applications across clinical environments.
Which All Ordinaries Healthcare Stock Gains on Trial News?
March 18, 2026 12:04 PM AEDT| By SamHealthcare stock activity within the All Ordinaries highlights clinical progress and sector participation, reflecting ongoing developments in biotechnology and research-driven industries.
Recce Webinar to Spotlight Phase 3 and Pipeline Progress
March 17, 2026 03:52 PM AEDT| By SamRecce Pharmaceuticals Ltd (ASX:RCE) will host a webinar covering Phase 3 trials, anti-infective pipeline updates, and a US Army research collaboration for burn wound treatment.
Is All Ordinaries Biotech Innovation Driving Precision Medicine?
March 17, 2026 01:49 PM AEDT| By SamTetraTherix advances precision medicine initiatives through biomaterial technology and collaborative biotechnology research, highlighting healthcare innovation within the broader All Ordinaries biotech landscape.
Is ASX All Ords Focus Turning to Prescient Therapeutics?
March 17, 2026 01:37 PM AEDT| By SamPrescient Therapeutics operates within the biotechnology sector conducting oncology research and clinical trial programs focused on developing cancer treatment technologies.
ASX 100 Healthcare Leader Sonic Healthcare in Focus
March 17, 2026 01:27 PM AEDT| By SamSonic Healthcare operates a global network of pathology laboratories and diagnostic imaging centres that support medical testing services within healthcare systems and the broader ASX healthcare sector.
Is ASX 300 Focus Turning to Clarity Pharma Activity?
March 17, 2026 12:13 PM AEDT| By SamClarity Pharmaceuticals operates in the biotechnology sector developing radiopharmaceutical technologies focused on cancer diagnostics and targeted oncology research.
Tetramatrix Push Expands Global Reach for (ASX:TTX)
March 16, 2026 07:21 PM AEDT| By SamTetratherix expands its Tetramatrix platform through a precision medicine franchise and US collaboration, advancing nasal drug delivery technology while strengthening its presence in regenerative medicine and biotechnology innovation.
Cochlear (ASX:COH) Gains Attention Across ASX 50 on Implant Tech
March 16, 2026 07:12 PM AEDT| By SamCochlear Limited activity within the ASX 50 highlights implantable hearing technology, global healthcare distribution networks, and ongoing advancements in medical device innovation.
Clarity Pharma (ASX:CU6) AMPLIFY Trial Consent Completed, ASX 300 Watch
March 16, 2026 06:00 PM AEDT| By SamClarity Pharmaceuticals activity within the ASX 300 reflects progress in radiopharmaceutical research as a prostate cancer imaging trial advances through clinical development stages.
AI Autism Diagnostic Study Network Expands Across U.S.
March 16, 2026 03:42 PM AEDT| By SamA new autism diagnostic study network in the United States advances smartphone-based AI healthcare tools, marking an important milestone in digital diagnostics and the future of technology-driven clinical assessment.
Healthcare Stocks in Focus Amid Global Market Uncertainty
March 13, 2026 09:43 PM AEDT| By SamAustralian healthcare stocks remain active despite global uncertainty as biotech companies progress drug trials, regulatory reviews, and partnerships, keeping the sector in focus across the broader Australian equities market.
EVE Health Expands Reformulated Drug Development Strategy
March 13, 2026 08:23 PM AEDT| By SamEVE Health Group strengthens its pharmaceutical reformulation strategy with new funding aimed at advancing innovative drug delivery technologies, regulatory development, and intellectual property initiatives targeting major global therapeutic markets...
Immutep Halts Key Lung Cancer Trial, Refocuses Strategy
March 13, 2026 08:09 PM AEDT| By SamImmutep halts its TACTI-004 lung cancer trial following a futility assessment, extending cash runway and prompting a strategic shift in its immunotherapy research pathway and broader oncology development programs.
Telix Trial Safety Update Draws Fresh Market Attention
March 13, 2026 06:01 PM AEDT| By SamTelix Pharmaceuticals advances its oncology pipeline as Phase trial safety data for TLX591-Tx strengthens focus on precision radiopharmaceutical therapies and evolving imaging-driven cancer treatment strategies.
Sonic Healthcare Valuation Debate Gains Market Attention
March 13, 2026 05:35 PM AEDT| By SamSonic Healthcare valuation debate intensifies as revenue growth meets profitability pressure. Explore diagnostics demand trends, regulatory risks, and margin recovery prospects shaping the outlook for this global pathology provider.
ASX 200 Healthcare Stocks Slide as Sector Faces Tough Week
March 13, 2026 04:35 PM AEDT| By SamRecent reporting season updates placed the ASX healthcare sector in focus as biotechnology firms, diagnostic providers, and medical service companies released operational developments and corporate announcements.
ASX 200 Watch: CSL Buy-Back Activity Draws Market Attention
March 13, 2026 11:25 AM AEDT| By SamCSL’s continued share repurchase activity highlights strategic capital management within Australia’s biotechnology sector and reflects how large corporations balance innovation investment with shareholder value initiatives.
ASX 200 Watch: What Immutep’s Efti Trial Shift Means Now
March 13, 2026 10:41 AM AEDT| By SamA clinical trial update from Immutep highlights the challenges of immunotherapy development while reinforcing the ongoing scientific pursuit of innovative cancer treatments within Australia’s biotechnology sector.
ASX Healthcare Buzz: Clinical Milestone Lifts Market Focus
March 13, 2026 10:35 AM AEDT| By SamHighlights,Clinical research updates sparked strong market attention in a healthcare listing,Elevated trading activity highlighted renewed focus on biotechnology progress,Funding developments strengthened visibility around the next stage of medical s...
Advertise your brand on Kalkine Media